[Nephrological aspects of congestive cardiac failure].
Moiseev
S V
SV
Fomin
V V
VV
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D051399:Aquaporin 2; D051403:Aquaporin 6; D020346:Aquaporins / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D006333:Heart Failure / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D007674:Kidney Diseases / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D020097:Natriuretic Peptide, Brain / Q000009:adverse effects / Q000627:therapeutic use; D014667:Vasopressins / Q000037:antagonists & inhibitors / Q000096:biosynthesis
C496023:AQP2 protein, human; D000806:Angiotensin-Converting Enzyme Inhibitors; D051399:Aquaporin 2; D051403:Aquaporin 6; D020346:Aquaporins; D014667:Vasopressins; D020097:Natriuretic Peptide, Brain